EVP R&D, Chief Medical Officer
Thu, Jan 30, 2025
Jan 30
exercised or converted securities in ALKS
23,542 shares @ $24.59
Increased holdings by +22.80%
Net across this filing: -6.90% (-3,286 shares)
Option Exercise
Sale tied to a same-time option exercise